Cong Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cong Huang has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Hongwu Chen
The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China
4 shared publicationsTingting Deng
The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China
4 shared publicationsZhenhao Li
Department of General Surgery Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumors Nanfang Hospital Southern Medical University Guangzhou China
4 shared publicationsBaizhi Li
Department of Gastrointestinal Surgery The First Affiliated Hospital of Shantou University Medical College Shantou 515041 China
2 shared publicationsHuaiming Wang
The First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China
2 shared publications- Huaiming Wang
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College
2 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1) , 915
Ultrasound-activated Cu2−XSe/TiO2 heterostructured nanosonosensitizer enables coordinated induction of ferroptosis and cuproptosis for tumor immunotherapy
- 27 September 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1) , 915
Open AccessUltrasound-activated Cu2−XSe/TiO2 heterostructured nanosonosensitizer enables coordinated induction of ferroptosis and cuproptosis for tumor immunotherapy
- Open Access
- 29 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (20) , e14318
Inulin‐Based Oral Chemotherapy Modulates Gut Microbiota and Immune Microenvironment through Inhibition of Neutrophil Extracellular Trap Formation for Improving Cancer Therapy
Despite the potential of chemoimmunotherapy against colorectal cancer (CRC) development, adverse reactions and drug resistance hinder its clinical uptake. Dysbiosis of the gut microbiota and neutrophil extracellular traps (NETs) formation are implicated in the increasing prevalence of chemoimmunotherapy resistance, which will need to be regulated to enable effective chemotherapy against CRC. To improve CRC therapy, inulin‐based oral chemotherapy microspheres (ZIF‐8@OXA@Inulin) are constructed. Oral inulin‐based microspheres specifically adapt to the digestive system, which accurately release drugs in response to pH variations in the gastrointestinal tract. Moreover, ZIF‐8@OXA@Inulin significantly enhances the intratumoral concentration and retention time of chemotherapeutic agents in an orthotopic colon tumor model, thereby further promoting pyroptosis. Additionally, ZIF‐8@OXA@Inulin microspheres reshape the gut microbiota by increasing the abundance of beneficial bacterial genera ( Alistipes , Lactobacillus , Enterorhabdus , and Turicibacter ) and suppressing the formation of NETs induced by chemotherapy‐associated side effects, ultimately facilitating T cell infiltration within the tumor microenvironment. ZIF‐8@OXA@Inulin microspheres not only demonstrate excellent anti‐tumor performance and antimetastatic effect but also exhibit adjuvant effects to immunotherapy agents. Collectively, the oral inulin‐based microspheres (ZIF‐8@OXA@Inulin) are capable of exhibiting anti‐tumor activities while promoting chemotherapy and immunotherapy effects. Therefore, they show substantial application potential for CRC therapy.
- 29 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (20) , e14318
Open AccessInulin‐Based Oral Chemotherapy Modulates Gut Microbiota and Immune Microenvironment through Inhibition of Neutrophil Extracellular Trap Formation for Improving Cancer Therapy
Despite the potential of chemoimmunotherapy against colorectal cancer (CRC) development, adverse reactions and drug resistance hinder its clinical uptake. Dysbiosis of the gut microbiota and neutrophil extracellular traps (NETs) formation are implicated in the increasing prevalence of chemoimmunotherapy resistance, which will need to be regulated to enable effective chemotherapy against CRC. To improve CRC therapy, inulin‐based oral chemotherapy microspheres (ZIF‐8@OXA@Inulin) are constructed. Oral inulin‐based microspheres specifically adapt to the digestive system, which accurately release drugs in response to pH variations in the gastrointestinal tract. Moreover, ZIF‐8@OXA@Inulin significantly enhances the intratumoral concentration and retention time of chemotherapeutic agents in an orthotopic colon tumor model, thereby further promoting pyroptosis. Additionally, ZIF‐8@OXA@Inulin microspheres reshape the gut microbiota by increasing the abundance of beneficial bacterial genera ( Alistipes , Lactobacillus , Enterorhabdus , and Turicibacter ) and suppressing the formation of NETs induced by chemotherapy‐associated side effects, ultimately facilitating T cell infiltration within the tumor microenvironment. ZIF‐8@OXA@Inulin microspheres not only demonstrate excellent anti‐tumor performance and antimetastatic effect but also exhibit adjuvant effects to immunotherapy agents. Collectively, the oral inulin‐based microspheres (ZIF‐8@OXA@Inulin) are capable of exhibiting anti‐tumor activities while promoting chemotherapy and immunotherapy effects. Therefore, they show substantial application potential for CRC therapy.
- Open Access
- 24 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (19) , e2500652
A Copper‐Based Photothermal‐Responsive Nanoplatform Reprograms Tumor Immunogenicity via Self‐Amplified Cuproptosis for Synergistic Cancer Therapy
Studies show that intracellular accumulation of copper ions causes cuproptosis, potentially enhancing anticancer immunity. However, the induction of cuproptosis inevitably faces challenges due to low intracellular copper deliver efficiency and collateral damage to normal tissues. This paper presents a self‐amplified cuproptosis nanoplatform (CEL NP) composed of Cu2−XS hollow nanospheres (HNSs), elesclomol (ES), and phase‐change material lauric acid (LA). Under NIR‐II laser irradiation, the photothermal energy generated by Cu2−XS HNSs melts LA, facilitating the precise release of ES and copper ions within the tumor microenvironment. Notably, ES can traverse the cell membrane and form ES‐Cu(II) complexes, thereby enhancing copper delivery within tumor cells. Excess Cu(II) also reacts with endogenous glutathione, reducing its inhibitory effect on cuproptosis. Ultimately, this amplified cuproptosis effect can activate immunogenic cell death, eliciting a robust immune response and promoting tumor suppression. The CEL NP‐mediated release of ES and copper ions offers a novel approach for anticancer therapy through cuproptosis induction.
- 24 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (19) , e2500652
Open AccessA Copper‐Based Photothermal‐Responsive Nanoplatform Reprograms Tumor Immunogenicity via Self‐Amplified Cuproptosis for Synergistic Cancer Therapy
Studies show that intracellular accumulation of copper ions causes cuproptosis, potentially enhancing anticancer immunity. However, the induction of cuproptosis inevitably faces challenges due to low intracellular copper deliver efficiency and collateral damage to normal tissues. This paper presents a self‐amplified cuproptosis nanoplatform (CEL NP) composed of Cu2−XS hollow nanospheres (HNSs), elesclomol (ES), and phase‐change material lauric acid (LA). Under NIR‐II laser irradiation, the photothermal energy generated by Cu2−XS HNSs melts LA, facilitating the precise release of ES and copper ions within the tumor microenvironment. Notably, ES can traverse the cell membrane and form ES‐Cu(II) complexes, thereby enhancing copper delivery within tumor cells. Excess Cu(II) also reacts with endogenous glutathione, reducing its inhibitory effect on cuproptosis. Ultimately, this amplified cuproptosis effect can activate immunogenic cell death, eliciting a robust immune response and promoting tumor suppression. The CEL NP‐mediated release of ES and copper ions offers a novel approach for anticancer therapy through cuproptosis induction.
- Open Access
- 24 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Biomimetic gene delivery system coupled with extracellular vesicle–encapsulated AAV for improving diabetic wound through promoting vascularization and remodeling of inflammatory microenvironment
Adeno-associated virus (AAV)-mediated gene transfer has demonstrated potential in effectively promoting re-epithelialization and angiogenesis. AAV vector has a safety profile; however, the relatively low delivery efficacy in chronic wound with an inflammatory microenvironment and external exposure has limited its prospective clinical translation. Here, we generated AAV-containing EVs (EV-AAVs) from cultured HEK 293T cells and confirmed that the gene transfer efficiency of VEGF-EV-AAV significantly surpassed that of free AAV. Subsequently, a biomimetic gene delivery system VEGF-EV-AAV/MSC-Exo@FHCCgel developing, and synergistically enhances anti-inflammation and transfection efficiency in the combination of human umbilical cord mesenchymal stem cell-derived exosomes (hUC-MSC-Exo). Upon reaching physiological temperature, this hydrogel system transitions to a gel state, maintaining AAV bioactivity and facilitating a sustained release of the encapsulated vesicles. The encapsulation strategy enables the vesicles to rapidly fuse with endothelial cell membranes, ensuring controlled expression of endogenous VEGF. Results revealed that VEGF-EV-AAV/MSC-Exo@FHCCgel alleviates mitochondrial function in endotheliocyte under oxidative stress. Furthermore, it eliminates senescent macrophages by inhabitation of cyclic GMP-AMP (cGAMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway to promote efferocytosis. The system increases Treg cells accumulation, leading to a reduction of inflammatory cytokines. Collectively, the biomimetic gene delivery system represents a promising multi-faceted strategy for chronic wound healing.
- 24 March 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Open AccessBiomimetic gene delivery system coupled with extracellular vesicle–encapsulated AAV for improving diabetic wound through promoting vascularization and remodeling of inflammatory microenvironment
Adeno-associated virus (AAV)-mediated gene transfer has demonstrated potential in effectively promoting re-epithelialization and angiogenesis. AAV vector has a safety profile; however, the relatively low delivery efficacy in chronic wound with an inflammatory microenvironment and external exposure has limited its prospective clinical translation. Here, we generated AAV-containing EVs (EV-AAVs) from cultured HEK 293T cells and confirmed that the gene transfer efficiency of VEGF-EV-AAV significantly surpassed that of free AAV. Subsequently, a biomimetic gene delivery system VEGF-EV-AAV/MSC-Exo@FHCCgel developing, and synergistically enhances anti-inflammation and transfection efficiency in the combination of human umbilical cord mesenchymal stem cell-derived exosomes (hUC-MSC-Exo). Upon reaching physiological temperature, this hydrogel system transitions to a gel state, maintaining AAV bioactivity and facilitating a sustained release of the encapsulated vesicles. The encapsulation strategy enables the vesicles to rapidly fuse with endothelial cell membranes, ensuring controlled expression of endogenous VEGF. Results revealed that VEGF-EV-AAV/MSC-Exo@FHCCgel alleviates mitochondrial function in endotheliocyte under oxidative stress. Furthermore, it eliminates senescent macrophages by inhabitation of cyclic GMP-AMP (cGAMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway to promote efferocytosis. The system increases Treg cells accumulation, leading to a reduction of inflammatory cytokines. Collectively, the biomimetic gene delivery system represents a promising multi-faceted strategy for chronic wound healing.
- Open Access
- 27 January 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101521
Multifunctional liposome boosts glioma ferroptosis and immunotherapy through reinforcement of chemo-dynamic therapy strategy
- 27 January 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101521
Open AccessMultifunctional liposome boosts glioma ferroptosis and immunotherapy through reinforcement of chemo-dynamic therapy strategy
- 8 March 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (11) , 13481-13495
Improved Immune Response for Colorectal Cancer Therapy Triggered by Multifunctional Nanocomposites with Self-Amplifying Antitumor Ferroptosis
Ferroptosis, as a type of regulated cell death, can trigger the release of damage-associated molecular patterns from cancer cells and lead to the enhancement of immune recognition. Fenton reaction-mediated chemodynamic therapy could initiate ferroptosis by generating lipid peroxides, but its efficiency would be greatly restricted by the insufficient H2O2 and antioxidant system within the tumor. Herein, this work reports the successful preparation of H2O2 self-supplied and glutathione (GSH)-depletion therapeutic nanocomposites (Cu2O@Au) through in situ growth of Au nanoparticles on the surface of cuprous oxide (Cu2O) nanospheres. Upon delivery into cancer cells, the released Cu2O could consume endogenous H2S within colorectal cancer cells to form Cu31S16 nanoparticles, while the released Au NPs could catalyze glucose to generate H2O2 and gluconic acid. The self-supplying endogenous H2O2 and lower acidity could amplify the Cu ion-induced Fenton-like reaction. Meanwhile, the consumption of glucose would reduce GSH generation by disrupting the pentose phosphate pathway. Additionally, the Cu2+/Cu+ catalytic cycle promotes the depletion of GSH, leading to lipid peroxide accumulation and ferroptosis. It was found that the onset of ferroptosis triggered by Cu2O@Au could initiate immunologic cell death, promote dendritic cell maturation and T-cell infiltration, and finally enhance the antitumor efficacy of the PD-L1 antibody. In summary, this collaborative action produces a remarkable antitumor effect, which provides a promising treatment strategy for colorectal cancer.
- 8 March 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (11) , 13481-13495
Improved Immune Response for Colorectal Cancer Therapy Triggered by Multifunctional Nanocomposites with Self-Amplifying Antitumor Ferroptosis
Ferroptosis, as a type of regulated cell death, can trigger the release of damage-associated molecular patterns from cancer cells and lead to the enhancement of immune recognition. Fenton reaction-mediated chemodynamic therapy could initiate ferroptosis by generating lipid peroxides, but its efficiency would be greatly restricted by the insufficient H2O2 and antioxidant system within the tumor. Herein, this work reports the successful preparation of H2O2 self-supplied and glutathione (GSH)-depletion therapeutic nanocomposites (Cu2O@Au) through in situ growth of Au nanoparticles on the surface of cuprous oxide (Cu2O) nanospheres. Upon delivery into cancer cells, the released Cu2O could consume endogenous H2S within colorectal cancer cells to form Cu31S16 nanoparticles, while the released Au NPs could catalyze glucose to generate H2O2 and gluconic acid. The self-supplying endogenous H2O2 and lower acidity could amplify the Cu ion-induced Fenton-like reaction. Meanwhile, the consumption of glucose would reduce GSH generation by disrupting the pentose phosphate pathway. Additionally, the Cu2+/Cu+ catalytic cycle promotes the depletion of GSH, leading to lipid peroxide accumulation and ferroptosis. It was found that the onset of ferroptosis triggered by Cu2O@Au could initiate immunologic cell death, promote dendritic cell maturation and T-cell infiltration, and finally enhance the antitumor efficacy of the PD-L1 antibody. In summary, this collaborative action produces a remarkable antitumor effect, which provides a promising treatment strategy for colorectal cancer.
- Open Access
- 29 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1324959
Identification and characterization of CLEC11A and its derived immune signature in gastric cancer
Introduction: C-type lectin domain family 11 member A (CLEC11A) was characterized as a growth factor that mainly regulates hematopoietic function and differentiation of bone cells. However, the involvement of CLEC11A in gastric cancer (GC) is not well understood.Methods: Transcriptomic data and clinical information pertaining to GC were obtained and analyzed from publicly available databases. The relationships between CLEC11A and prognoses, genetic alterations, tumor microenvironment (TME), and therapeutic responses in GC patients were analyzed by bioinformatics methods. A CLEC11A-derived immune signature was developed and validated, and its mutational landscapes, immunological characteristics as well as drug sensitivities were explored. A nomogram was established by combining CLEC11A-derived immune signature and clinical factors. The expression and carcinogenic effects of CLEC11A in GC were verified by qRT−PCR, cell migration, invasion, cell cycle analysis, and in vivo model analysis. Myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), M2 macrophages, and T cells in tumor samples extracted from mice were analyzed utilizing flow cytometry analysis.Results: CLEC11A was over-expressed in GC, and the elevated CLEC11A expression indicated an unfavorable prognosis in GC patients. CLEC11A was involved in genomic alterations and associated with the TME in GC. Moreover, elevated CLEC11A was found to reduce the benefit of immunotherapy according to immunophenoscore (IPS) and the tumor immune dysfunction, exclusion (TIDE). After validation, the CLEC11A-derived immune signature demonstrated a consistent ability to predict the survival outcomes in GC patients. A nomogram that quantifies survival probability was constructed to improve the accuracy of prognosis prediction in GC patients. Using shRNA to suppress the expression of CLEC11A led to significant inhibitions of cell cycle progression, migration, and invasion, as well as a marked reduction of in vivo tumor growth. Moreover, the flow cytometry assay showed that the knock-down of CLEC11A increased the infiltration of cytotoxic CD8+ T cells and helper CD4+ T into tumors while decreasing the percentage of M2 macrophages, MDSCs, and Tregs.Conclusion: Collectively, our findings revealed that CLEC11A could be a prognostic and immunological biomarker in GC, and CLEC11A-derived immune signature might serve as a new option for clinicians to predict outcomes and formulate personalized treatment plans for GC patients.
- 29 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1324959
Open AccessIdentification and characterization of CLEC11A and its derived immune signature in gastric cancer
Introduction: C-type lectin domain family 11 member A (CLEC11A) was characterized as a growth factor that mainly regulates hematopoietic function and differentiation of bone cells. However, the involvement of CLEC11A in gastric cancer (GC) is not well understood.Methods: Transcriptomic data and clinical information pertaining to GC were obtained and analyzed from publicly available databases. The relationships between CLEC11A and prognoses, genetic alterations, tumor microenvironment (TME), and therapeutic responses in GC patients were analyzed by bioinformatics methods. A CLEC11A-derived immune signature was developed and validated, and its mutational landscapes, immunological characteristics as well as drug sensitivities were explored. A nomogram was established by combining CLEC11A-derived immune signature and clinical factors. The expression and carcinogenic effects of CLEC11A in GC were verified by qRT−PCR, cell migration, invasion, cell cycle analysis, and in vivo model analysis. Myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), M2 macrophages, and T cells in tumor samples extracted from mice were analyzed utilizing flow cytometry analysis.Results: CLEC11A was over-expressed in GC, and the elevated CLEC11A expression indicated an unfavorable prognosis in GC patients. CLEC11A was involved in genomic alterations and associated with the TME in GC. Moreover, elevated CLEC11A was found to reduce the benefit of immunotherapy according to immunophenoscore (IPS) and the tumor immune dysfunction, exclusion (TIDE). After validation, the CLEC11A-derived immune signature demonstrated a consistent ability to predict the survival outcomes in GC patients. A nomogram that quantifies survival probability was constructed to improve the accuracy of prognosis prediction in GC patients. Using shRNA to suppress the expression of CLEC11A led to significant inhibitions of cell cycle progression, migration, and invasion, as well as a marked reduction of in vivo tumor growth. Moreover, the flow cytometry assay showed that the knock-down of CLEC11A increased the infiltration of cytotoxic CD8+ T cells and helper CD4+ T into tumors while decreasing the percentage of M2 macrophages, MDSCs, and Tregs.Conclusion: Collectively, our findings revealed that CLEC11A could be a prognostic and immunological biomarker in GC, and CLEC11A-derived immune signature might serve as a new option for clinicians to predict outcomes and formulate personalized treatment plans for GC patients.
- 12 April 2022
- Published by IOP Publishing in Nanotechnology
- Vol. 33 (27) , 275101
Hydroxyapatite nanoparticles promote mitochondrial-based pyroptosis via activating calcium homeostasis and redox imbalance in vascular smooth muscle cells
Hydroxyapatite nanoparticles (HAP) have been widely used in various fields because of their natural biological origin and functional properties. The emerging evidence on their toxicities has attracted research interest. HAP-induced vascular smooth muscle cell (VSMC) damage is a key step in vascular calcification (VC), particularly in patients with chronic kidney disease. However, the injury effects and mechanism of action of HAP on VSMCs have not been extensively investigated. This study comprehensively characterized commercially available HAP and investigated its adverse biological effects in cultured A7R5 cells. In vitro experiments revealed that internalized HAP was localized in lysosomes, followed by the release of Ca 2+ owing to the low pH microenvironment. Upon Ca 2+ homeostasis, Ca 2+ enters the mitochondria, leading to the simultaneous generation of reactive oxygen species (ROS). ROS subsequently attack mitochondrial transmembrane potentials, promote mitochondrial ROS production, and oxidize mitochondrial DNA (Ox-mtDNA). Mitochondrial permeability-transition pores open, followed by the release of more Ox-mtDNA from the mitochondria into the cytosol due to the redox imbalance. This activates NLRP3/caspase-1/gasdermin D-dependent pyroptosis and finally excretes inflammatory factors to induce VC; an antioxidant could rescue this process. It has been suggested that HAP could induce an imbalance in intracellular Ca 2+ homeostasis in A7R5 cells, followed by the promotion of mitochondrial dysfunction and cell pyroptosis, finally enhancing VC. To detect the in vivo toxicity of HAP, mice were treated with Cy7-labelled HAP NPs for 24 h. In vivo results also demonstrated that HAP accumulated in the kidneys, accompined with increased Ca concentration, upregulated oxidative stress-related factor and kidney damage. Overall, our research elucidates the mechanism of calcium homeostasis and redox imbalance, providing insights into the prevention of HAP-induced cell death.
- 12 April 2022
- Published by IOP Publishing in Nanotechnology
- Vol. 33 (27) , 275101
Hydroxyapatite nanoparticles promote mitochondrial-based pyroptosis via activating calcium homeostasis and redox imbalance in vascular smooth muscle cells
Hydroxyapatite nanoparticles (HAP) have been widely used in various fields because of their natural biological origin and functional properties. The emerging evidence on their toxicities has attracted research interest. HAP-induced vascular smooth muscle cell (VSMC) damage is a key step in vascular calcification (VC), particularly in patients with chronic kidney disease. However, the injury effects and mechanism of action of HAP on VSMCs have not been extensively investigated. This study comprehensively characterized commercially available HAP and investigated its adverse biological effects in cultured A7R5 cells. In vitro experiments revealed that internalized HAP was localized in lysosomes, followed by the release of Ca 2+ owing to the low pH microenvironment. Upon Ca 2+ homeostasis, Ca 2+ enters the mitochondria, leading to the simultaneous generation of reactive oxygen species (ROS). ROS subsequently attack mitochondrial transmembrane potentials, promote mitochondrial ROS production, and oxidize mitochondrial DNA (Ox-mtDNA). Mitochondrial permeability-transition pores open, followed by the release of more Ox-mtDNA from the mitochondria into the cytosol due to the redox imbalance. This activates NLRP3/caspase-1/gasdermin D-dependent pyroptosis and finally excretes inflammatory factors to induce VC; an antioxidant could rescue this process. It has been suggested that HAP could induce an imbalance in intracellular Ca 2+ homeostasis in A7R5 cells, followed by the promotion of mitochondrial dysfunction and cell pyroptosis, finally enhancing VC. To detect the in vivo toxicity of HAP, mice were treated with Cy7-labelled HAP NPs for 24 h. In vivo results also demonstrated that HAP accumulated in the kidneys, accompined with increased Ca concentration, upregulated oxidative stress-related factor and kidney damage. Overall, our research elucidates the mechanism of calcium homeostasis and redox imbalance, providing insights into the prevention of HAP-induced cell death.